Batteryless Neurostimulator Shows Promising 6-Month Results for Overactive Bladder Treatment
Key Insights
Neuspera (search)'s novel batteryless sacral neuromodulation system demonstrates 84% response rate in treating urgency urinary incontinence (search) at 6-month follow-up.
The innovative device eliminates the need for a battery implant, requiring only a single incision for placement and utilizing external power transmission through a wearable disc.
Clinical outcomes match established efficacy benchmarks for traditional sacral neuromodulation therapy while offering a less invasive surgical approach.
A groundbreaking batteryless neurostimulation system has demonstrated strong clinical efficacy in treating overactive bladder (search) symptoms, according to 6-month data presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2025 Winter Meeting.
The SANS-UUI phase II study evaluated Neuspera (search)'s ultra-miniaturized sacral neuromodulation system, which achieved an 84% response rate among patients with urgency urinary incontinence (search). Response was defined as at least a 50% reduction in urgency incontinence episodes.
Revolutionary Battery-Free Design
Unlike conventional sacral neuromodulators that require both a stimulation lead and an implanted battery pack, Neuspera (search)'s system operates without an internal power source. The device consists solely of an implanted lead containing integrated stimulation components, powered externally through a wearable disc placed over the skin.
"The ultimate in making the battery really, really small is, well, what if we didn't have a battery at all?" explains Dr. Colin Goudelocke, a urologist at Ochsner Health Center in Covington, Louisiana. "It's very innovative in that way."
Simplified Surgical Approach
The battery-free design significantly simplifies the implantation procedure. Traditional systems require two incisions – one for the lead and another for the battery generator typically placed in the upper buttocks or lower waist area. The new device needs only a single incision for the lead placement, potentially reducing surgical complexity and recovery time.
Patient-Friendly Operation
The system's external power source is incorporated into a wearable garment containing the transmission disc, allowing patients to maintain normal daily activities while receiving therapy. "You can walk around with it. You can clean the house or read a book or watch television or do whatever you want to do," notes Dr. Goudelocke.
Clinical Implications
The 6-month efficacy data aligns with historical response rates seen with traditional sacral neuromodulation devices, suggesting the batteryless system could provide a less invasive alternative without compromising treatment effectiveness.
"Those of us who do this a lot, we always feel like the more tools that we have in our toolbox, the better we're able to service our patients," Dr. Goudelocke adds. "If I have different options for different people, I think I can do a lot more good for a lot more people."
The positive results from this phase II study mark an important advancement in neuromodulation therapy, potentially offering patients and clinicians a new option that combines proven efficacy with reduced surgical burden.